• Home TyRx announced in that Mason Diamond.

TyRx announced in that Mason Diamond.

Week period. A Phase I study of its therapeutic vaccine TG4040 For patients chronically infected with the hepatitis C virus.

Embryo donation and adoption is a relatively new practice in the United States. Nightlight by his Snowflake program, the birth of 165 babies has implemented on the road on the road. There are still an estimated 500,000 frozen embryos in storage around the country and increasingly are donated for adoption every month.

In January 2006, Transgene a 1.3 million grant was awarded by the Lyonbiopole Competitiveness Cluster for the development of its therapeutic vaccine TG4040 against hepatitis C chronic infection. The funding, which comes from the French Ministry of Industry, is expected 30 percent of the 30 percent of research and development costs for this program.In May 2006, TyRx announced in that Mason Diamond, vice president of, Clinical and Regulatory Affairs, as industry representative in the FDA was elected Device Advisory Committee Dental Products panels the Center for Devices and Radiological Health.

Designed of an exclusive license with a Baylor College of Medicine and The University of Texas MD Anderson Cancer Center for using three product patents and the technologies involved by the two bodies entered on to develop innovative cardio or surgical medical instruments develop with the problem of the problem of postoperative nosocomial infections.

About TyRx Pharma – has TyRx organizes in the year 1998 in order combinatorial chemistry is combinatorial chemistry -based biomaterial technology exclusively from Rutgers, The State University of New Jersey licenses, degradable substances such as tyrosine to biological medical quality build polymers. Use proprietary polymerization processes TyRx efficiency updated on tailor polymers of to comply precise product specifications. TyRx be making their capabilities in a wide range of combined preparations.